TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Orthocell Ltd ( (AU:OCC) ) has shared an announcement.
Orthocell Ltd announced a change in the director’s interest, with Michael McNulty acquiring 24,561 ordinary shares through an on-market purchase. This transaction reflects a strategic move by the director to increase his stake in the company, potentially signaling confidence in Orthocell’s future growth and market positioning.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd operates in the biotechnology industry, focusing on regenerative medicine. The company develops and commercializes innovative products for the repair and regeneration of soft tissue injuries, with a market focus on orthopedic and musculoskeletal conditions.
Average Trading Volume: 728,560
Technical Sentiment Signal: Buy
Current Market Cap: A$308.8M
See more insights into OCC stock on TipRanks’ Stock Analysis page.